Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.
Status:
Completed
Trial end date:
2016-12-13
Target enrollment:
Participant gender:
Summary
A randomized two-arm study comparing preoperative CRT using oral capecitabine versus bolus
5-FU/LV concomitant to external beam radiation (50.5 Gy/28 fractions) for locally advanced
rectal cancer. Main outcome was clinical response assessed using MRI and endorectal US 6-8
weeks after CRT. Secondary endpoints were pathological response, adverse effects, sphyncter
preservation, quality of life, OS and DFS.